Posted by Michael Wonder on 23 Jan 2023
RenalGuard Therapy receives FDA breakthrough device designation for prevention of cardiac surgery associated AKI
20 January 2023 - CardioRenal Systems announced today that the FDA granted breakthrough device designation for its RenalGuard Therapy device for the prevention of acute kidney injury in patients at risk for cardiac surgery associated acute kidney injury.
RenalGuard is designed to protect the kidneys with personalised, active hydration. This is achieved by maximising urine output, while balancing hydration via real time urine output monitoring and intravenous infusion in a smart rehydration system.
